“This week, heads of state, celebrities and CEOs will attend U.N. Secretary General Ban Ki-moon’s ‘Every Woman, Every Child’ dinner in New York,” an event that “will highlight the amazing contribution of the Global Fund to Fight AIDS, Tuberculosis and Malaria to the health of women and children in developing countries,” Lucy Chesire, executive director and secretary to the board of TB ACTION Group, writes in the Huffington Post’s “The Big Push” blog. “Ten years ago, tackling HIV, tuberculosis [TB] and malaria seemed an almost impossible task. Today we can see the beginning of the end of these three killer diseases,” she continues, adding, “But to make these historic achievements possible we need sufficient resources available!”
Forbes features an interview with Deborah Derrick, president of Friends of the Global Fight Against AIDS, Tuberculosis and Malaria, in which she “discusse[s] her motivations for pursuing a career in international affairs and social change, her experience as a senior program officer at the [Bill & Melinda Gates Foundation], what lessons she learned during her time at Gates that are most applicable in her new executive role at Friends of the Global Fight, the current landscape of challenges and solutions, and the role of technology in accelerating progress.” In the interview, Derrick said, “The mobilization to defeat these diseases in the past decade has been stunningly successful. … But there is so much more that needs to be done. If we don’t muster the resources to keep up the fight, and all commit to doing our part in a time of constrained resources, we risk backsliding on the progress we’ve already invested in” (Kanani, 9/21).
“[O]ver the past month, [tuberculosis (TB)] has captured high-profile attention from the Washington Post, the New York Times, TIME, NPR, [Agence France-Presse] and other major media, generating big headlines about the rising challenge we face in tackling one of humanity’s oldest and most resilient infectious diseases,” Jan Gheuens, interim director of the Bill & Melinda Gates Foundation’s TB Program, writes in the foundation’s “Impatient Optimists” blog. “Why should we be concerned?” he asks. Gheuens says because the worldwide number of multidrug-resistant TB (MDR-TB) cases is growing; “it costs a lot of money to treat MDR-TB”; and “MDR-TB patients must go through two years of intensive treatment, including daily injections for the first six months.” He concludes, “What’s clear now, more than ever, is that making progress on TB will require a comprehensive approach that includes new and better approaches to diagnosis, treatment, and prevention” (9/6).
“The Global Fund to Fight AIDS, Tuberculosis and Malaria [on Monday] released the funding recommendations of its Technical Review Panel for the Transitional Funding Mechanism,” the Stop TB Partnership reports in an article on its webpage. “Grant proposals for tuberculosis (TB) received 25 percent ($127.4 million) of all the approved funding ($510 million) — a marked increase over the historic average share of 16 percent since the Global Fund was established in 2002,” the article notes, adding, “TB applications were also most successful, with an 86 percent recommendation rate; malaria applications engendered a 79 percent recommendation rate and HIV proposals a 62 percent recommendation rate” (8/21).
“While the battle against HIV/AIDS attracts more donor funding globally than all other diseases combined, it has not diverted attention from fighting unrelated afflictions — such as malaria, measles and malnutrition — and may be improving health services overall in targeted countries, according to a study on Rwanda published” Wednesday in the American Journal of Tropical Medicine and Hygiene, an American Society of Tropical Medicine and Hygiene (ASTMH) press release reports. “A six-year investigation of health clinics in Rwanda by researchers at Brandeis University infuses fresh evidence into a long-standing debate about whether the intensive focus on HIV/AIDS, which in 2010 alone killed 1.8 million people, is undermining other health services, particularly in African countries that are at the epicenter of the pandemic,” the press release states (5/2).
“A third of the world’s population is carrying tuberculosis [TB], and the disease could become incurable if governments fail to act, the World Health Organization (WHO) has warned,” noting that a “[l]ack of funding for public health programs, the sale of inaccurate blood tests and the misuse of drugs, particularly in the private health sector, are hampering the fight against the disease and leading to drug resistance,” the Independent reports. “The rate of TB deaths had declined dramatically — by 40 percent between 1990 and 2000 — after a worldwide health campaign, which was particularly successful in China,” but “the emergence of drug-resistant strains threatens to halt progress and jeopardizes the WHO’s goal of eradicating the disease as a public health problem by 2050,” the newspaper writes, noting, “Two billion people are carriers of the TB bacillus” globally.
“[P]articipants at a symposium held last week by the U.K. Consortium on AIDS and International Development warned that [progress on HIV and tuberculosis (TB) vaccines] could be jeopardized by the recent downturn in global health funding,” BMJ reports. The journal summarizes comments made at the meeting by researchers and advocacy group representatives, who stressed that successful vaccines for HIV and TB would save millions in existing research investments and long-term treatment costs (Moszynski, 5/22).
The Global Fund to Fight AIDS, Tuberculosis and Malaria “expects to have an additional $1.6 billion to fund projects in 2012-2014, [the fund's General Manager Gabriel Jaramillo] said on Wednesday, a turnaround from a funding freeze last year,” Reuters reports (Miles, 5/9). “The new funds are a result of ‘strategic decisions made by the Board, freeing up funds that can be invested in countries where there is the most pressing demand,’ a statement by the fund said,” according to PlusNews (5/10). “The money includes funds from new donors, from traditional donors who are advancing their payments or increasing contributions and from some donors, such as China, that have offered to support projects in their own country to free up cash for more pressing needs elsewhere, Jaramillo said,” Reuters notes (5/9). “This forecast is better than expected, and it comes from the fantastic response we are getting to our transformation,” Jaramillo said, adding, “But we need more to get the job done. Countries that implement our grants are saving more and more people, but demand for services is still enormous,” according to the statement (5/9).
GlobalPost’s “Global Pulse” blog reports on a potential public-private partnership that aims to bring tuberculosis (TB) vaccine trials to the gold mines of Southern Africa, where, “[f]or every 100,000 workers …, 3,000 have tuberculosis, and many have often-fatal, drug-resistant strains of TB.” The blog writes that mining company “Anglo American announced Tuesday at the GBCHealth Conference [in New York] that it has agreed in principle to make its mines available for TB vaccine trials organized by Aeras, a non-profit that has 12 TB vaccine candidates now in various stages of research,” noting, “No formal agreement has been reached, but Anglo American’s spokesman vowed to make it happen.”
“For the first time in India, 12 people have been detected with totally drug-resistant lung tuberculosis (TDR-TB), a condition in which patients do not respond to any TB medication” and for which the mortality rate is 100 percent, the Hindustan Times reports. “Doctors treating these patients say the absolute resistance is a result of the patients being prescribed wrong antibiotics,” the newspaper reports (1/7). “While Iran first reported TDR-TB cases three years ago, India seems to be only the second country to report this deadly form of the disease,” the Times of India notes (Iyer, 1/7).